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Induced pluripotent stem cells (IPSCs), are pluripotent stem cells obtained from somatic cells by the
transient expression of four transcription factors: Oct4, Sox2, Klf4, C-Myc (OSKM). IPSCs are able to
differentiate to any cell type. Therefore iPSC technology might be used to generate cells and used in
regenerative medicine.
Myocardial infarction (MI) and derived complications are a source of high morbidity and mortality in the
world. After MI, cardiomyocytes are replaced by fibrotic non-functional tissue and many complications
can occur. IPSCs technology could be used to reverse the pathologic effects of MI.
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The material used in this scientific review has been mainly obtained from books and scientific databases such as Pubmed, Google scholar and
Researchgate. The literature was selected by journal relevance and sometimes limited to the past 5 years in order to obtain actual information.
Some of the key words used were: myocardial infarction, iPSCs, scafolds, cardiomyocyte differentiation, reprogramming factors, among others.
Introduction
Reprogramming iPSCs Differentiation
Cell source 
IPSCs use limitations
ObjectivesMethods
Results
Conclusions
Delivery
Oct4 Sox2
C-Myc Klf4
Neural cells
Hepatocytes
Cardiac cells
iPSC
Somatic cell MI
Cardiac rupture Congestive heart failure Arrythmia
Figure 1. IPSC generation
from a somatic cell. Later it
can be differentiated into
any cell type [*].
Figure 2. MI, and
some complications
derived of it.
Adapted from [1].
The aim of this review is to study translational aspects of induced pluripotent stem cell technology in cardiac repair after myocardial infarction. This will
be achieved by illustrating the current state of the art of this technology and, furthermore, by evaluating the limitations for clinical translation.
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Vectors are needed to introduce the OSKM
reprogramming factors into somatic cells to induce
pluripotency.
Integrative vectors
Sendai Virus
Episomal Plasmid
mRNAs
Non integrative vectors
Retrovirus
Lentivirus
4 3
1 2
• iPSCs can differentiate to cardiac cells in vitro and in
vivo
• iPSCs derived cardiac cells produce therapeutic effects
in hearts after suffering from MI.
• Therapeutic effects mainly occur through paracrine
signaling.
• Combination of multiple cell types, tissue engineering
and prosurvival factors enhance graft therapeutic effect
• Some problems still need to be solved before clinical
translation is occur
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Figure 3. Current methods for
iPSC cardiac differentiation.
Adapted from [2]. GF: growth
factor
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A combination of cardiac pluripotent cells and
their derivatives seem to act synergistically
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Figure 4. Cardiac cell therapy using iPSCs
derivatives. CPC: Cardiac progenitor cell; CM:
Cardiomyocyte; EC: Endothelial cell [*]
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Figure 5. Combined approach
for amelioration injured heart.
dECM: decellularized extracellular
matrix. Based on [3]
